Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

NCT03456466 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-hodgkin's Lymphoma

Interventions

DRUG: TQB2303
DRUG: Rituximab

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.